Treatment of Amelanocytic Melanoma with Asymptomatic Brain Metastases

When amelanocytic melanoma spreads to the brain without causing neurological symptoms, treatment planning requires a specific, evidence-guided approach. The asymptomatic presentation is a clinically meaningful window: therapy chosen at this stage shapes both intracranial control and systemic outcomes.

Clinical Scenario

Patients with asymptomatic melanoma brain metastases (MBMs) — detectable on imaging but not yet causing symptoms — require structured first-line therapy. Timely treatment selection is critical to prevent neurological deterioration and preserve treatment options.

Treatment Approach

Upfront combination immunotherapy is the preferred systemic strategy for eligible patients. In parallel, all patients with brain metastases should be evaluated for a brain-directed local intervention. For patients unsuitable for immunotherapy, an alternative pathway exists that depends on molecular tumour profiling — the full selection criteria, agent choices, and decision algorithm are in the complete protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.annonc.2024.11.006

Patients with asymptomatic MBMs should preferably be treated upfront with nivolumabeipilimumab [II, A].

Patients with MBMs should be evaluated for stereotactic radiosurgery (SRS) [III, B].

If unsuitable for immunotherapy, patients with asymptomatic MBMs and BRAF V600-mutated melanoma can be offered BRAFieMEKi [III, B; ESCAT I-A].

View source ↗